| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 597 | 2020 |
| Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials RG Simonetti, A Liberati, C Angiolini, L Pagliaro Annals of Oncology 8 (2), 117-136, 1997 | 500 | 1997 |
| Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients M Esposito, M Venturini, MO Vannozzi, G Tolino, G Lunardi, O Garrone, ... Journal of clinical oncology 17 (4), 1132-1132, 1999 | 74 | 1999 |
| Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity M Venturini, G Lunardi, L Del Mastro, MO Vannozzi, G Tolino, G Numico, ... Journal of clinical oncology 18 (10), 2116-2125, 2000 | 60 | 2000 |
| Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice CA Garcia-Etienne, RE Mansel, M Tomatis, J Heil, L Biganzoli, A Ferrari, ... The Breast 45, 89-96, 2019 | 45 | 2019 |
| Appropriateness and variation of surgical treatment of breast cancer in Italy: when excellence in clinical research does not match with generalized good quality care N Scorpiglione, A Nicolucci, R Grilli, C Angiolini, M Belfiglio, F Carinci, ... Journal of clinical epidemiology 48 (3), 345-352, 1995 | 40 | 1995 |
| Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer M Venturini, L Del Mastro, O Garrone, C Angiolini, M Merlano, ... Annals of oncology 13 (4), 546-552, 2002 | 38 | 2002 |
| Cost profiles of colorectal cancer patients in Italy based on individual patterns of care S Francisci, S Guzzinati, M Mezzetti, E Crocetti, F Giusti, G Miccinesi, ... BMC cancer 13, 1-11, 2013 | 35 | 2013 |
| Comparing cancer care, outcomes, and costs across health systems: charting the course J Lipscomb, KR Yabroff, MC Hornbrook, A Gigli, S Francisci, M Krahn, ... Journal of the National Cancer Institute Monographs 2013 (46), 124-130, 2013 | 35 | 2013 |
| Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study A Caldarella, G Amunni, C Angiolini, E Crocetti, F Di Costanzo, A Di Leo, ... International Journal for Quality in Health Care 24 (4), 411-418, 2012 | 32 | 2012 |
| Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen G Bertelli, M Valenzano, S Costantini, R Rissone, C Angiolini, A Signorini, ... Gynecologic oncology 78 (3), 275-277, 2000 | 32 | 2000 |
| The influence of patient characteristics on the appropriateness of surgical treatment for breast cancer patients A Nicolucci, F Mainini, A Penna, N Scorpiglione, R Grilli, C Angiolini, ... Annals of oncology 4 (2), 133-140, 1993 | 27 | 1993 |
| Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States A Gigli, JL Warren, KR Yabroff, S Francisci, M Stedman, S Guzzinati, ... Journal of the National Cancer Institute Monographs 2013 (46), 88-98, 2013 | 19 | 2013 |
| Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data S Francisci, S Guzzinati, G Capodaglio, D Pierannunzio, S Mallone, ... The European Journal of Health Economics 21, 1003-1013, 2020 | 16 | 2020 |
| Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian … S Gori, F Puglisi, M Cinquini, G Pappagallo, A Frassoldati, L Biganzoli, ... European Journal of Cancer 99, 9-19, 2018 | 14 | 2018 |
| Severe thrombocytopenia after trastuzumab retreatment: a case report MS Pino, C Angiolini, L Fioretto BMC research notes 6, 1-3, 2013 | 13 | 2013 |
| Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients. G Bertelli, P Queirolo, S Vecchio, C Angiolini, M Bergaglio, L Del Mastro, ... Anticancer research 20 (5C), 3659-3661, 2000 | 6 | 2000 |
| Capecitabine in Association with Epirubicin and Docetaxel as First Line Chemotherapy in Advanced Breast Cancer: A Dose-Finding Study C Angiolini, M Venturuni, L Del Mastro, G Tolino, O Garrone, M Merlano, ... BREAST CANCER RESEARCH AND TREATMENT 64 (1), 529-529, 2000 | 6 | 2000 |
| Integrating mammography screening programmes into specialist breast centres in Italy: insights from a national survey of Senonetwork breast centres S Deandrea, F Ferrè, R D’Antona, C Angiolini, M Bortul, L Bucchi, ... BMC Health Services Research 22 (1), 723, 2022 | 3 | 2022 |
| Promuovere il miglioramento della pratica clinica: le linee guida R Grilli, C Angiolini, F Mainini, A Penna, A Liberati EPIDEMIOLOGIA E PREVENZIONE 17, 114-117, 1993 | 3 | 1993 |
Giovanni FilardoSouthern Methodist University and Baylor UniversityVerified email at aya.yale.edu
